CAC
EIDX

Cowen and Company’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Cowen and Company’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,427
Closed -$325K – 632
2020
Q3 		$325K Buy
+6,427
New +$289K 0.05% 170
2020
Q1 		– Sell
-46,949
Closed -$2.69M – 587
2019
Q4 		$2.69M Buy
+46,949
New +$2.32M 0.23% 40

Other funds holding EIDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Cowen and Company's EIDX Position: Q4 2020 in Review

Cowen and Company sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q4 2020, closing a stake of 6,427 shares — an estimated $325K sold.

Cowen and Company first reported a position in EIDX in Q4 2019 and held it in 2 quarters. The position peaked at $2.69M in Q4 2019. 121 funds tracked by Wall St. Rank hold EIDX as of Q4 2020.

  • Cowen and Company reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Cowen and Company sold 6,427 Eidos Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $325K.
  • Cowen and Company first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • Cowen and Company's Eidos Therapeutics, Inc. Common Stock position peaked at $2.69M in Q4 2019.
  • 121 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Cowen and Company's 13F filing for Q4 2020, filed 8 Feb 2021.